ASNC/Pfizer Young Investigator in Cardiac Amyloidosis Research Fellowship Award

The award provides $35,000 of support to eligible investigators for a mentored research project exploring the role of nuclear cardiology in the early detection of TTR cardiac amyloidosis.

Congratulations to Ramsey Wehbe, MD recipient of the 2021 ASNC/Pfizer Young Investigator in Cardiac Amyloidosis Research Award


  • Increase opportunities for clinical research focused on cardiac amyloidosis and to improve early diagnosis, timely referral to amyloid experts, and knowledge of emerging treatment options.
  • Improve outcomes of patients with ATTR-CM.
  • Encourage and support careers in nuclear cardiology research while growing the science of cardiac imaging and advancing the specialty.


  • Promote research in nuclear cardiology among young investigators.
  • Create platform for research projects in the area of advancing early detection of TTR cardiac amyloidosis utilizing nuclear cardiology.
  • Provide an "initial" grant for young investigators that will serve as a stepping stone to larger awards.
  • Promote the field of nuclear cardiology by supporting new and innovative research. 

Award Amount/Project Duration

$35,000 for one year

Number of Awards

One (1)

Award Eligibility

Individuals who:
  • Hold an MD, PhD or equivalent degree
  • Are post-doctoral fellows or faculty in the first three years of appointment on the date of the application deadline
  • Intend to pursue an academic career in nuclear cardiology
  • Have an active ASNC membership
Individuals with prior independent investigator awards (e.g., NIH, R0l) will not be eligible to apply for this funding.
The applicant may not have current overlapping funding from another organization to supplement their proposed work.

Judging Criteria

Applications will be reviewed against the following criteria:
  • Scientific merit (significance) with focus on the potential for the project to generate data for a successful peer-reviewed grant application
  • Approach/methods
  • Innovation and role in early detection or monitoring of TTR cardiac amyloidosis
  • Investigator qualifications with focus on the potential for the principal investigator to develop into an independent investigator
  • Quality of mentor and training environment – letter of reference from mentor
  • Research benefit for the field of nuclear cardiology
A rating scale such as the one below will be utilized by the award committee for scoring each application.
A numerical scoring system from 1.0 to 5.0 -- 1.0 is highest; 2.5 is mid-range; 5.0 is lowest.


Applications must be submitted online at no later than July 5, 2022.

Sponsored by: Pfizer Inc.